Stockscreener 앱 받기
88.46
0.07%
0.06
시간 외 거래:
88.41
-0.05
-0.06%
Gilead Sciences Inc 주식(GILD)의 최신 뉴스
Gilead announces impending layoffs, facility closure - LabPulse
26 Analysts Assess Gilead Sciences: What You Need To Know - Benzinga
Royal Bank of Canada Forecasts Strong Price Appreciation for Gilead Sciences (NASDAQ:GILD) Stock - MarketBeat
Amid Seattle downsizing, Gilead cuts 100+ positions at California HQ - FiercePharma
Gilead’s Livdelzi shows promise in PBC clinical trial - Clinical Trials Arena
Gilead Sciences shares target upgraded, holds rating on HIV event outlook - Investing.com India
5,715 Shares in Gilead Sciences, Inc. (NASDAQ:GILD) Bought by Aljian Capital Management LLC - MarketBeat
Gilead Sciences, Inc. (NASDAQ:GILD) Shares Bought by TrinityPoint Wealth LLC - MarketBeat
Nurix Therapeutics Presents Preclinical Data from Two Autoimmune and Inflammatory Disease Programs, NX-5948 and GS-6791, at ACR Convergence 2024 - GlobeNewswire Inc.
Gilead Sciences, Inc. (NASDAQ:GILD) Shares Purchased by Swiss National Bank - MarketBeat
Thrivent Financial for Lutherans Boosts Stake in Gilead Sciences, Inc. (NASDAQ:GILD) - MarketBeat
14,342 Shares in Gilead Sciences, Inc. (NASDAQ:GILD) Bought by Atlanta Consulting Group Advisors LLC - MarketBeat
How Gilead Sciences' HIV & Other Innovations Are Set to Capture Untapped Markets & Drive Massive Growth!Major Drivers - Smartkarma
Gilead Sciences, Inc. (NASDAQ:GILD) Shares Sold by Kentucky Retirement Systems - MarketBeat
CIBC Asset Management Inc Purchases 22,624 Shares of Gilead Sciences, Inc. (NASDAQ:GILD) - MarketBeat
Impax Asset Management Group plc Sells 7,979 Shares of Gilead Sciences, Inc. (NASDAQ:GILD) - MarketBeat
Gilead’s Irish business sees profit slump on falling sales of Covid drug - The Irish Times
Gilead to see Bay Area layoffs in wake of Seattle office closingSan Francisco Business Times - The Business Journals
Gilead Sciences Inc. stock underperforms Friday when compared to competitors - MarketWatch
Form 424B5 GILEAD SCIENCES, INC. - StreetInsider.com
Biotech giant Gilead lays off 104 from Bay Area headquarters, including execs - SFGATE
Cell Therapy Market Poised for Massive Growth (2024-2031) | Gilead Sciences, Inc., Novartis, AG, Vericel Corporation - openPR
Gilead Unveils Long-Term Data From Seladelpar In Patients With Rare Liver Disease - Yahoo Finance
Simplify Asset Management Inc. Buys New Holdings in Gilead Sciences, Inc. (NASDAQ:GILD) - MarketBeat
Gilead Sciences (GILD) Reports Livdelzi (Seladelpar) Demonstrated a Sustained Efficacy and Long-Term Safety Profile in Management of Primary Biliary Cholangitis - StreetInsider.com
Gilead’s Livdelzi (Seladelpar) Demonstrated a Sustained Efficacy and Long-Term Safety Profile in Management of Primary Biliary Cholangitis - Business Wire
Empowered Funds LLC Reduces Stock Holdings in Gilead Sciences, Inc. (NASDAQ:GILD) - MarketBeat
As an HIV+ activist, I know drug companies aren't doing enough to end AIDS - Yahoo News UK
Dearborn Partners LLC Has $26.76 Million Holdings in Gilead Sciences, Inc. (NASDAQ:GILD) - MarketBeat
Gilead Sciences, Inc. (NASDAQ:GILD) Shares Sold by Intellectus Partners LLC - MarketBeat
Citigroup Upgrades Gilead Sciences (NASDAQ:GILD) to Strong-Buy - MarketBeat
Gilead and Kite Are Cutting Employees, Closing Seattle, Philadelphia Sites - BioSpace
Gilead Sciences to close Seattle office; shutdown impacts 72 employees - MSN
COVID drugmaker to close Seattle office, lay off 72 workers - The Seattle Times
Gilead Sciences Inc. stock outperforms competitors despite losses on the day - MarketWatch
CAR T-Cell Therapy For Acute Lymphoblastic Leukemia Market on Track for Major Expansion by 2034, According to DelveInsight | Eli Lilly and Company, Gilead Sciences, Novartis, Autolus Therapeutics - Barchart
Gilead, Vertex initiated as new big biotech buys at Citi - Seeking Alpha
Gilead lays off 72 workers in Seattle, plans to shutter R&D support site - Fierce Biotech
ING Groep NV Acquires 109,788 Shares of Gilead Sciences, Inc. (NASDAQ:GILD) - MarketBeat
Gilead Sciences to Close Seattle Office, Lay Off 72 Employees Located at Alexandria’s 199 E. Blaine Property - The Registry Seattle
Gilead Sciences, Inc. (GILD) is Attracting Investor Attention: Here is What You Should Know - MSN
Brokers Suggest Investing in Gilead (GILD): Read This Before Placing a Bet - Yahoo Finance
Gilead Sciences, Inc. (NASDAQ:GILD) Shares Sold by KBC Group NV - MarketBeat
Gilead Sciences (NASDAQ:GILD) Coverage Initiated by Analysts at Citigroup - MarketBeat
Gilead Sciences, Inc. (NASDAQ:GILD) Shares Sold by Bell Bank - MarketBeat
Prime Capital Investment Advisors LLC Sells 14,908 Shares of Gilead Sciences, Inc. (NASDAQ:GILD) - MarketBeat
Gilead Prices $3.5 Billion of Senior Unsecured Notes - BioSpace
Biotech giant Gilead Sciences to close its Seattle office, lay off employees - The Business Journals
Gilead Sciences Raises $3.5B in Multi-Tranche Notes Offering with 40-Year Terms | GILD Stock News - StockTitan
Gilead data lends insight into transforming HIV prevention landscape - European Pharmaceutical Review
Gilead Sciences Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Gilead Sciences' SWOT analysis: stock outlook amid HIV dominance, pipeline progress - Investing.com India
Gilead reports positive HIV PrEP data for lenacapavir (NASDAQ:GILD) - Seeking Alpha
We Think You Can Look Beyond Gilead Sciences' (NASDAQ:GILD) Lackluster Earnings - Simply Wall St
Gilead Sciences' (NASDAQ:GILD) Soft Earnings Are Actually Better Than They Appear - Yahoo Finance
Gilead Foundation’s Healthcare Education, Access and Lead - CSRwire.com
ICICI Prudential Asset Management Co Ltd Sells 11,934 Shares of Gilead Sciences, Inc. (NASDAQ:GILD) - MarketBeat
SEC Form 424B5 filed by Gilead Sciences Inc. - Quantisnow
RPG Investment Advisory LLC Has $7.03 Million Stock Holdings in Gilead Sciences, Inc. (NASDAQ:GILD) - MarketBeat
Gilead Sciences (GILD) Presents Full PURPOSE 2 Data Results for Twice-Yearly Lenacapavir for HIV Prevention - StreetInsider.com
Gilead Presents Full PURPOSE 2 Data Results for Twice-Yearly Lenacapavir for HIV Prevention at HIV Glasgow - Yahoo Finance
Gilead Sciences, Inc. (NASDAQ:GILD) Stake Boosted by Sumitomo Mitsui Trust Group Inc. - MarketBeat
Gilead Sciences (GILD) Stock Surges 4% on Positive Drug Trials and Promising Obesity and Weight Loss Treatments - Barchart
Decoding Gilead Sciences Inc (GILD): A Strategic SWOT Insight - GuruFocus.com
HIV Drug Buyers Want Gilead Product Switch Claims Revived - Law360
Gilead Sciences Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
Bay Area lacks Black, Latino health care workers. $5M grant could help - ABC7 Bay Area
Victory Capital Management Inc. Sells 468,814 Shares of Gilead Sciences, Inc. (NASDAQ:GILD) - MarketBeat
Gilead Foundation's Healthcare Education, Access and Leadership (HEAL) Initiative Is Dedicating $5 Million to Help Build a More Diverse Bay Area Healthcare Workforce - Marketscreener.com
1.03%
1.71%
자본화:
|
볼륨(24시간):